

Better Antibodies By Design

Citi's European Healthcare Conference June 2015



Forward Looking Statement

This presentation contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably gualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Further, certain forward looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in this document speak only as at the date of this presentation.

Antibody Innovation Generating World Class Products



Focus on Cancer

- Differentiated human antibodies
- Track record breakthrough therapeutics

a seaso						
	-				-	
Desire gradurije kalana (SA)	-	_	_	_	_	
ulautar (capiture (P))	-	_	_	_	-	
Whee large & cell (matterne (1817))		_	_	_	-	
Rectangle and a second starts	-	_	_	_	-	
history waters to take a second (1997)	-	_	_			
Contemporte Procession de conte		_	_	-		
Naligia myakama (MM)	-	_	_	_	-	
Lifes Paried and Based				-		
land concern	-					
when Enhanced Bullion Automotics	-					

Robust Product Pipeline

- Ofatumumab cancer & autoimmune potential (marketed as Arzerra® in various CLL indications)
- Daratumumab blockbuster potential
- HuMax[®]-TF-ADC in Phase I solid cancers



Passion for Innovation

- World class antibody know-how
- Proprietary technologies DuoBody[®] & HexaBody[™]
- Innovative pre-clinical pipeline



Partnerships → Product Ownership


- · Key collaborations drive current pipeline
- Product opt-ins + retain products for future value
- Well capitalized



Innovative Pipeline

			Develo	pment Phase	
Product	Disease Indications	Pre- clinical	1.00	II	ш
Ofatumumab Target: CD20	Chronic lymphocytic leukemia (CLL)				
Indication: Cancer Partner: Novartis	Follicular lymphoma (FL)				
Ofatumumab Target: CD20	Pemphigus vulgaris (PV) (SubQ)				
Indication: Autoimmune	Relapsing remitting multiple sclerosis (RRMS) (SubQ)		Ann	ounced	
Partner: GSK	Neuromyelitis optica (NMO) (SubQ)		Announ	ced >	
Daratumumab Target: CD38	Multiple myeloma (MM)				
Partner: Janssen	Non-Hodgkin's Lymphoma (NHL)		Announ	ced	
HuMax-TF-ADC Target: TF Partner: Seattle Genetics	Solid Cancers				
Teprotumumab	Active thyroid eye disease				
Target: IGF-1R Partner: River Vision	Diabetic macular edema				
HuMax-TAC-ADC Target: CD25 Partner: ADCT	Lymphomas	Anno	ounced	×	
HuMax-IL8 Target: IL-8 Partner: Cormorant	Metastatic solid tumors	Anno	ounced	,	
➢ 20 Active Pre-clinical	Partnered programs: HuMab, DuoBody & HexaBody				
programs incl. HuMax-AXL-ADC	Proprietary programs: HuMab, HuMab-ADC, DuoBody, DuoBody-ADC & HexaBody				

Daratumumab (HuMax[®]-CD38) First-in-Class Antibody with Broad-Spectrum Killing Activity



Expansive Daratumumab Clinical Development 12 Ongoing or Announced Studies

	Disease Stage	Therapy	No.	Development Phase			
Indication			Pts*	I.	1/11	Ш	ш
	Smoldering	Mono**	120	SMM	12001 (Cer	ntaurus)	
		Dara + VMP	700		MMY300	7 (Alcyone	
	Front line (transplant & non-	Dara + Revlimid + Dex	730		MMY30	008 (Maia)	$ \rightarrow $
***	transplant)	Dara + VTD**	1,000		MMY3006	(Cassiope	ia)
oma	Multi combo: 1 Study	130	MMY1	001			
Myel		Dara + Revlimid + Dex	45		GEN503		
Multiple Myeloma***		Dara + Revlimid + Dex	560		MMY30	03 (Pollux)	\rightarrow
Mult	Relapsed or Refractory	Dara + Velcade + Dex	480		MMY300	04 (Castor)	\rightarrow
		Mono, Japan	12	MMY1	002		
		Mono, safety	112	GE	N501		
	Double Refractory	Mono, BTD population	124	M	MY2002 (S	irius)	
NHL (DLBCL / MCL / FL)	Relapsed or Refractory	Mono**	210	LY	M2001 (Ca	arina) 🔪	


Genmab

*Approx. no. based on clinicaltrials.gov **Study announced, first patient not yet dosed. ***Maintenance integrated into some study protocols VMP = bortezomib & melphalan-prednisone VTD = bortezomib, thalidomide & dexamethasone BTD = Breakthrough Therapy Designation₆




Positive Preliminary Results: Daratumumab Phase II Study in Double Refractory MM

Study Design




Daratumumab: Early Signs of Clinical Activity Ph I/II Revlimid Combo Study in Multiple Myeloma



- Part 1; ORR 100% (31% CR, 46% VGPR)
- Part 2; ORR 87% (7% CR, 43% VGPR)
- 75% VGPR or better in patients treated for at least 6 months

Genmab

Daratumumab: Early Signs of Clinical Activity Ph Ib MM Combo Study with Velcade / Pomalidomide Regimens



- ORR:
 - 100% in newly diagnosed group (Velcade combinations)
 - 54.5% in relapsed group –all <u>></u>VGPR (POM-D combination)

V, bortezomib; D, dexamethasone; DARA, daratumumab; M, melphalan; P, prednisone; T, thalidomide; POM, pomalidomide. sCR, stringent complete response; VGPR, very good partial response; PR, partial response; MR, minimal response; PD, progressive disease.

Arzerra[®] (ofatumumab)

Sales by GSK

- 2014 sales GBP 54.5M (~\$82.2M); royalty DKK 101M
- Genmab Cancer Royalty = 20%

Hrzerro® 10 steriit koncentrat steriili konsentraat Ofatumumab/Ofat i.v. 1000 mg/50 ml

Our First Marketed Product

- Human antibody targeting CD20 on cancerous B-cells
- Differentiated vs other CD20 mAb, targets slice of > \$8B market

Cancer

- Approved*
 - US 1st Line CLL in combo w/ chlorambucil
 - EU 1st Line CLL in combo w/ chlorambucil or bendamustine
 - Fludarabine and alemtuzumab refractory CLL
- Phase III trials in CLL & FL
- · Partnered with Novartis


Autoimmune diseases (unapproved)

- Phase III trial ongoing in PV
- Relapsing remitting MS Ph III's & pivotal NMO trials announced
- Partnered with GSK


*In US approved in combination with chlorambucil for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate as well as for the treatment of patients with CLL refractory to fludarabine and alemtuzumab.

In EU approved in combination with chlorambucil or bendamustine for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabinebased therapy, as well as for the treatment of patients with CLL refractory to fludarabine and alemtuzumab.


Ofatumumab: Planned & Ongoing Trials



HuMax[®]-TF-ADC: In the Clinic Next Generation Therapeutics



HuMax-TF-ADC in Patients with Solid Tumors Best Response and Duration of Follow-up





 Footnote: X denotes time of disease progression. Patients still in the trial have an "O" following the end of their bar. Dashed vertical line at 6 weeks denotes the SD-threshold, Not evaluable (because of insufficient follow-up) patients are denoted with an NE. SD: stable disease, PR: partial response.

HuMax-AXL-ADC Efficacy in *in vivo* Tumor Model

Fully Human Antibody-Drug Conjugate

- Targets AXL signaling molecule expressed on many solid cancers
- HuMax-AXL-ADC shows anti-tumor activity in patient-derived xenograft model with heterogeneous target expression
- Collaboration: Seattle Genetics







DuoBody[®] Technology Efficient & Versatile Platform for Bispecific Antibodies

DuoBody

- Dual-targeting, potential to improve specificity & efficacy
- Large scale manufacturing
 - Minimal protein engineering
 - Excellent quality BsAb at very high yields
- Differentiated from competitor platforms
 - Proper in vivo half-life
- Fc-effector functions
- Good manufacturability

Ongoing Collaborations

- 4 Commercial deals
- Novartis (2 progr., \$175M potential deal value + royalties)
- Janssen Biotech (20 progr., \$3.6B potential deal value + royalties)
- BioNovion (expansion research deal, joint development / ownership)
- BioNTech (joint development / ownership)
- 5 Research deals
 - Kirin, Cormorant, undisclosed major Biotech, Agenus, Humabs BioMed




HexaBodyTM Technology Robust Effector Function Enhanced Antibodies

HexaBody


*HexaBod

- Enables antibodies to readily form clusters of 6 (hexamers)
- Induces & enhances target cell killing after binding via CDC
- CDC capability to essentially any antibody
- Builds on natural antibody biology minimal engineering
- Create novel, differentiated products in cancer & infect. dis.
- Repurpose / rescue drug candidates that failed in Phase II/III
- Life cycle management
- Collab. w. undiscl. major Biotech, Humabs BioMed & Agenus

Genmab's Robust Innovative Pre-Clinical Pipeline







Well-Capitalized Biotech – 2015 Guidance

Income Statement	DKKM	USDM*	2015 Expense Base DKK 625M (\$90M)
Revenue	650 - 725	94 - 104	DKK 50M
Operating expenses	(600) – (650)	(86) – (94)	(\$7M) DKK 90M (\$13M)
Reversal of GSK Liability	175	25	DKK 165M (\$24M)
Operating income	200 - 275	29 - 40	26%
Cash position at end of year**	2,750 – 2,850	396 - 411	34%
*USD 1.00 = DKK 6.9 **Cash, cash equivale		ble securities	DKK 110M 18%
2015 Guidance – May 12, 20	15. Cash position increa	ised	 Development (\$30M) Research Salary Depreciation & Warrants
following employee warrant e			Uther 19



2015 Goals: Maximizing Pipeline Value

Priority	\checkmark	Targeted Milestone
Maximize daratumumab clinical progress	~	 » Phase II MM monotherapy data & - if favorable, discuss regulatory next steps with health authorities » Start multiple new MM trials » Start non-MM clinical trial
Optimize ofatumumab value	~	 » File for an additional indication » Phase III relapsed CLL data » Start Phase III sc autoimmune trials
Strengthen differentiated product pipeline	√	 » Phase I HuMax-TF-ADC data » Progress HuMax-AXL-ADC » Progress pre-clinical DuoBody & HexaBody projects
Broaden partnership portfolio with next generation technologies	 ✓ ✓ 	 » Expand DuoBody & HexaBody collaborations » Progress partnered programs » New IND filings
Disciplined financial management		» Maintain cost base while selectively investing to advance pipeline



On Track to a Sustainably Profitable Future



- Robust differentiated product pipeline
 - Daratumumab, ofatumumab, HuMax-TF-ADC
 - Innovative pre-clinical pipeline
- Proprietary technologies -DuoBody & HexaBody
- Partnerships → Product ownership
 - Well capitalized
- Positioned for success
 - For patients & shareholders



Better Antibodies By Design


Appendix



International Shareholder Base

- Major shareholders >5%
 - Johnson & Johnson Devel. Corp.
 - FMR (Fidelity)
 - ATP
- ADR program in USA
 - Ticker: GMXAY
 - Sponsored level 1
 - Ratio: 2 ADR: 1 ordinary share
 - Depositary Deutsche Bank
- Shares outstanding: 58,717,499
 - Total diluted shares: 62,266,433

Geographical Shareholder Distribution December 31, 2014*





Market Sizes Estimated Prevalence in 7 Major Markets

Disease	Estimated Incidence in 7 Major Markets ¹	Estimated Prevalence	Estimated Global Branded Sales by 2018
CLL	32,000	250,000	\$5.3B
FL	32,000	260,000	\$10.5B ²
MM	55,000	190,000	\$11.5B
RRMS	26,100 ³	370,600	\$18.5B ³

¹Incidence for MS does not include Japan

²Sales data is for NHL, which includes FL

³Data is for MS, which includes RRMS

Sources: CLL, DLBCL, FL 2013 forecast incidence: Datamonitor, "Pipeline Insight: Leukemias" and "Pipeline Insight: Lymphomas, Multiple Myeloma & Myelodysplastic Syndromes", March 2010.

CLL, DLBCL, FL prevalence based on median survival of 8 yrs: company estimates.

MM 2012 incidence: Datamonitor, "Multiple Myeloma Epidemiology", May 2013; MM prevalence: SEER 2012; company estimates.


MS incidence, "Atlas of MS 2013"

RRMS prevalence, Datamonitor, "Multiple sclerosis Epidemiology", May 2012.

Sales data for CLL, FL, MM based on EvaluatePharma® 2014, sales data for MS from Datamonitor, "Multiple Sclerosis Forecast", 3 February 2014.



Daratumumab Induces Superior CDC



	Daratumumab	MOR202* 1	SAR 650984 ^{1,2}
	(Genmab)	(MorphoSys)	(Sanofi-Aventis)
EC50 (μg/mL)	0.15	2.3	1.0
Maximum killing (%)	90	20	15

*MOR202 clone MOR03087; ¹:surrogate mAb produced in HEK cells, generated using VH and VL sequences as published PCT patent applications WO2012/041800 (MOR03087) and WO2008/047242 (38SB19); ²:38SB19

CD38 Landscape: Direct In-House Pre-Clinical Comparison with Surrogates of Competitor Antibodies

		Daratumumab (Genmab)	MOR202 ¹ (MorphoSys)	SAR 650984 ^{1, 2} (Sanofi-Aventis)	AB79 (Millennium/Takeda)
	Origin	Human	Human	Chimeric	Human
	Development phase	Phase III	Phase I/IIa	Phase I/II	Pre-clinical
	Binding ³	+++	++	+++	+++
	ADCC (max lysis) ³	++	++	++	++
	CDC (max lysis) ³	+++	+	+	++
Mechanism	Phagocytosis ^{3, 4}	+++	++	nd	+++
of Action	Ecto-enzyme function	+	-	+++	+
	Direct PCD 5, 6	-	-	++	-
	PCD after cross- linking ^{5, 6}	+++	+++	+++	+++


*MOR202 clone MOR03087; ¹:surrogate mAb produced in HEK cells, generated using VH and VL sequences as published in PCT applications WO2012/041800 (MOR03087) and WO2008/047242 (38SB19); ²:38SB19; ³:Daudi cells; ⁴:based on EC50 data, ⁵:Ramos cells ⁶: PCD: Programmed cell death, measured by Annexin V positivity and caspase-3 activation. nd = not determined




Daratumumab Beyond Multiple Myeloma Pre-clinical Activity in DLBCL & ALL

Effect daratumumab on tumor growth in patient-derived DLBCL model


Effect daratumumab with or without vincristine in ALL xenograft model





Janssen Daratumumab Clinical Trials in Multiple Myeloma: Smoldering

NCT 02316106 (SMM2001 Centaurus) Enrolling Soon (1Q15): 120 Est. Pts




1 Cycle = 8 Weeks

Primary Endpoints: CR & Time to Progression to Symptomatic Multiple Myeloma

Genmab


Janssen Daratumumab Clinical Trials in Multiple Myeloma: **Frontline Non-Transplant**

NCT 02195479 (MMY3007 Alcyone) Enrolling Now: 700 Est. Pts




Janssen Daratumumab Clinical Trials in Multiple Myeloma: Frontline Transplant

MMY3006 (Cassiopeia) Enrolling Soon (2Q15): 1,000 Est. Pts: Part 1



Genmab Janssen Daratumumab Clinical Trials in Multiple Myeloma: **Relapsed or Refractory**

NCT 02076009 (MMY3003 Pollux) Enrollment Complete, Except Japan: 560 Est. Pts





2014 & 2015 Ofatumumab Data

Ofatumumab maintenance prolongs PFS in relapsed CLL

- Population
 - Pts in CR or PR after 2nd & 3rd line treatment for CLL
 - Ofatumumab vs Observation
- Key Safety Data
 - Grade 3 & 4 AEs
 - Ofatumumab 25%
 - Observation 17%
- Key Efficacy Data
 - PFS
 - Ofatumumab 28.6 months
 - Observation 15.2 months
- Conclusion
 - Ofatumumab maintenance provided significant clinical benefit for pts with relapsed CLL
 - Well-tolerated with no unexpected toxicities

Ofatumumab + fludarabine + cyclophosphamide met primary endpoint of improved PFS in Relapsed CLL

- Population
 - Pts with relapsed CLL
 - Ofatumumab + fludarabine + cyclophosphamide vs fludarabine + cyclophosphamide
- Key Safety Data
 - Consistent with other trials of ofatumumab
 - No new safety signals observed
- Key Efficacy Data
 - PFS
 - OFC 28.9 months
 - FC 18.8 months
 - ORR
 - •84% OFC
 - •68% FC


Ofatumumab + Idelalisib in Previously Treated CLL

Population	Key safety data	Key efficacy data	Conclusion
 Relapsed CLL within 24 month after last therapy Median 3 prior lines of therapy Ofatumumab + idelalisib vs ofatumumab in 2:1 randomization Open label trial 	 Diarrhea/colitis 20%, pneumonia 12.7%, febrile neutropenia 11.6% Safety manageable with a profile similar to previously observed in CLL 	 Ofatumumab +idelalisib ORR 75.3% Median PFS 16.3 m Median OS 20.9 m Ofatumumab ORR 18% Median PFS 8 m Median OS 19.4 m 	 Met primary endpoint Combination of ofatumumab and idelalisib safe and feasible



Ofatumumab

Potential to Combine with Tyrosine Kinase Inhibitors




Sources:


Da Roit et al. "Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy." Abstract. EHA 2014

Jaglowski et al. "A Phase Ib/II study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) and related diseases." ASCO 2014


HuMax-TF-ADC in Patients with Solid Tumors Best Percent Reduction from Baseline



Footnote: as per RECIST 1.1 (green), PSA (CRPC patients only, yellow), CA125 (ovarian cancer patients only, purple).




Pre-study (August 2014)




Post therapy (May 2015)







Immuno-Oncology Turning Cancer into a Chronic Condition



Immuno-Oncology Genmab as Key Player: Two Commercial Deals

BioNovion

- Expansion of previous research collaboration
- Co-development agreement
- Bispecific antibodies to immuno-oncology targets to be created with DuoBody technology

BioNTech

- Co-development and commercialization agreement
- Collaboration will focus on multiple product candidates in field of immuno-oncology
- BioNTech provides antibody panels



Better Antibodies By Design

